SUBSCRIBE
SUBSCRIBE
News   FDA

FDA Gives Go Ahead for Actavis’ Irinotecan Hydrochloride Injection

March 14, 2008 | 
1 min read
MORRISTOWN, NJ--(Marketwire - March 14, 2008) - Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection, a cancer drug, from the US Food & Drug Administration (FDA).
FDA Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Megaphone with stethoscope isolated on orange background. 3d illustration
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Regulatory
FDA Mulls ‘Regulatory Action’ on Argenx’s Vyvgart Hytrulo Over Severe Safety Concerns
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
 · 
1 min read
 · 
Lori Ellis